Rank the most well-adapted cancer treatments
Bionov™ provides a scored and ranked listing of the most well-adapted personalized medicine treatment options. The comprehensive analysis considers commonly used treatments, as well as targeted therapy, immunotherapy, hormone therapy, and newly approved oncology drugs. These options are presented either alone (monotherapy) or in combinations of up to 4 drugs.

Filter out therapies that are expected to have poor outcomes
Many cancer treatments are ineffective and can lead to drug resistance, added cost, and side-effects. Bionov™ can rank therapies against its databases of genes, pathways, and drug characteristics to predict which therapies are associated with improved outcomes.

Input your own combination therapy options
Combination therapy has been used widely to treat other diseases such as HIV/AIDS, and recent studies have shown it to be effective in cancer. However, its adoption has been limited in cancer due to its complexity. Bionov™ allows you to see where your own proposed combinations rank alongside other highly ranked options.


The patient receives a solid/liquid biopsy, and the sample is sent to a 3rd party service provider for tumor profiling. Bionov™ can input data from most tumor profiling companies, and can analyze most types of biological data (DNA sequencing, protein expression, etc.), or even integrate multiple types of data.

Bionov™ uses its software platform to analyze your genetic information and compare it with our large database of information from medical experts, other patients, clinical trials, and published data.

Bionov™ generates an analysis which scores and ranks the most well-adapted treatment options.

Bionov™ enables the physician to make the most informed treatment decisions, considering the most advanced personalized treatment options.




Bionov™ performs the multi-parametric analyses required to analyze millions of combination options.

Bionov™ platform incorporates custom curated databases of publications, clinical trials, genes, pathways, and drug characteristics.

Bionov™ looks at a patient’s mutations together rather than individually, such that it can analyze options that target multiple mutations rather than single drug therapies targeting individual mutations.

Bionov™ integration spans many types of biological data.

Bionov™ is agnostic to tumor profiling company data.


Track Record

The Bionov™ approach has been used on thousands of patients since its initial development at the UC San Diego Moores Cancer Center and San Diego Supercomputer Center. Some recent Case Studies are provided.


Cross-disciplinary Expertise

The Bionov™ approach has been built upon a foundation of discoveries in oncology, genomics, molecular biology, and many other cross-disciplinary fields. Key Publications are provided.



Most cancers harbor a cocktail of genomic alterations or mutations. Personalized medicine has typically focused on targeting what the oncologist considers to be the most important mutation, using a single “targeted” drug.

Bionov™ is unique in that it looks at all of a patient’s mutations together rather than individually. This enables drug combination recommendations targeting multiple mutations rather than single drug therapies.

Bionov™ also integrates multiple types of biological results (DNA sequencing, protein expression, etc.) into its comprehensive analysis, and considers commonly-used cancer treatments as well all of the latest advances in cancer care, including immunotherapy, targeted therapy, hormone therapy, and newly approved cancer drugs.

The resulting analysis ranks the top 2-, 3-, and 4- drug combinations (out of more than 4.5 million options) that are customized for each individual patient.

The analysis is not a substitute for a physician’s decision, but rather it empowers the physician to make the most informed decision, using the most advanced personalized treatment options. The clear analysis layout and ranking is designed to provide actionable knowledge and insight to the oncologist.